Hydroxychloroquine-d4 (sulfate) (Synonyms: HCQ-d4) |
|
Catalog No.GC47445
|
An internal standard for the quantification of hydroxychloroquine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1854126-45-6
Sample solution is provided at 25 µL, 10mM.
Hydroxychloroquine-d4 (sulfate) is intended for use as an internal standard for the quantification of hydroxychloroquine by GC- or LC-MS. Hydroxychloroquine is an aminoquinoline with antimalarial, anti-inflammatory, and antiviral activities.1,2,3,4 It is active against the chloroquine-sensitive NF54 and D6 strains of P. falciparum (IC50s = 16.3 and 15 nM, respectively) but has decreased activity against chloroquine-resistant P. falciparum strains (IC50s = 422.7-1,735.3 nM).1 Hydroxychloroquine inhibits production of IL-22, IL-17A, and IL-6 induced by phorbol 12-myristate 13-acetate and ionomycin in peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals or patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).5 It inhibits accumulation of sequestosome-1 (SQSTM1) puncta, a marker of autophagy, in mouse embryonic fibroblasts (MEFs) in a concentration-dependent manner.2 Hydroxychloroquine reduces viral titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the culture supernatant of infected Vero E6 cells but does not reduce SARS-CoV-2 viral titers in an in vitro human airway epithelium model or the respiratory tract of infected cynomolgus macaques.4 Formulations containing hydroxychloroquine have been used in the prevention or treatment of malaria, as well as in the treatment of RA and SLE.
1.Delves, M., Plouffe, D., Scheurer, C., et al.The activities of current antimalarial drugs on the life cycle stages of Plasmodium: A comparative study with human and rodent parasitesPLoS Med.9(2)e1001169(2012) 2.Mauthe, M., Orhon, I., Rocchi, C., et al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy14(8)1435-1455(2018) 3.da Silva, J.C., Mariz, H.A., da Rocha, L.F., Jr., et al.Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patientsClinics (Sao Paulo)68(6)766-771(2013) 4.Maisonnasse, P., Guedj , J., Contreras, V., et al.Hydroxychloroquine use against SARS-CoV-2 infection in non-human primatesNature585(7826)584-587(2020) 5.Yi, J., Zhu, J., Wu, J., et al.Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesisProc. Natl. Acad. Sci. USA202017152(2020)
| Cas No. | 1854126-45-6 | SDF | |
| Synonymes | HCQ-d4 | ||
| Canonical SMILES | CC(CCCN(CC)C([2H])([2H])C([2H])([2H])O)NC1=CC=NC2=CC(Cl)=CC=C21.O=S(O)(O)=O | ||
| Formula | C18H22D4ClN3O.H2SO4 | M.Wt | 438 |
| Solubility | Water: 100 mM | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2831 mL | 11.4155 mL | 22.8311 mL |
| 5 mM | 456.6 μL | 2.2831 mL | 4.5662 mL |
| 10 mM | 228.3 μL | 1.1416 mL | 2.2831 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)















